Why Estrogen Pills Are Contraindicated in Breastfeeding Mothers
Estrogen-containing oral contraceptives should be deferred until at least 3-6 weeks postpartum in breastfeeding mothers primarily due to increased risk of venous thromboembolism during the postpartum period, with a secondary concern that estrogen may suppress lactation and reduce milk quantity and quality. 1
Primary Concern: Venous Thromboembolism Risk
The postpartum period itself carries an inherently elevated risk of venous thromboembolism (VTE), and estrogen-containing contraceptives further compound this risk. Combined hormonal contraceptives are prohibited during the six weeks following childbirth due to this thrombogenic concern 2. The evidence shows that:
- Combined oral contraceptives increase VTE risk by approximately 4-fold in general populations 2
- This risk is dose-dependent, with higher estrogen doses (50 mcg) carrying greater risk than lower doses (30 mcg) 2
- The postpartum state represents a hypercoagulable period with multiple risk factors including age ≥35 years, immobility, obesity (BMI ≥30), postpartum hemorrhage, and post-cesarean delivery 1
Secondary Concern: Impact on Lactation
Estrogen has documented effects on milk production and composition:
- Estrogen suppresses lactation, reducing both the quantity and quality of breast milk, with decreased percentages of proteins and fats 3
- Studies examining combined oral contraceptives show inconsistent but concerning effects on breastfeeding performance, with some demonstrating greater supplementation needs and decreased breastfeeding continuation 4
- Recent evidence indicates that vaginal rings with low-dose ethinylestradiol (15 mcg/day) reduce self-reported expressed breastmilk volume by 20%, though oral pills with 20 mcg/day showed no significant impact 5
Safe Alternatives During Breastfeeding
Progestin-only methods can be safely started immediately postpartum and represent the only acceptable hormonal contraceptive option during the first 6 weeks 2, 1. The evidence supporting progestin-only contraception is reassuring:
- Microdose progestin pills (levonorgestrel 30 mcg, desogestrel 75 mcg) show no significant increase in VTE risk 2
- Progestin-only methods do not affect hemostatic parameters when used in small doses 2
- Clinical impression suggests no adverse effect on lactation performance with progestin-only pills 6, 3
- Long-acting reversible contraception (LARC) methods including implants and IUDs are highly effective and unaffected by breastfeeding 7
Clinical Algorithm for Postpartum Contraception
Weeks 0-6 postpartum:
- Progestin-only pills, implants, or IUDs only
- Absolutely avoid all estrogen-containing methods
- Barrier methods acceptable
After 6 weeks postpartum:
- Combined hormonal contraceptives may be considered if breastfeeding is not exclusive or if woman accepts potential impact on milk supply
- Continue to prefer progestin-only or non-hormonal methods for fully breastfeeding women
- Screen for additional VTE risk factors (obesity, smoking, age >35, thrombophilia) before prescribing estrogen
Important Caveats
One study found an excess risk of type 2 diabetes among breastfeeding Latin American women with gestational diabetes history using microdose progestins, with relative risk of 2.87 overall and 4.92 after >8 months exposure 2. However, this finding has not been confirmed in other populations and may be specific to the breastfeeding state.
The evidence base examining modern low-dose estrogen formulations in breastfeeding women remains limited, with most older studies using higher estrogen doses (≥30 mcg) that are less commonly prescribed today 4. Despite theoretical improvements with lower doses, the fundamental concerns about VTE risk in the early postpartum period and potential lactation suppression remain valid reasons for contraindication.